TNFRSF10B and plasma cell myeloma: Circularly permuted TRAIL (CPT) is tested in myeloma and some antibodies have also been developed: an anti-TRAIL-R (dulanermin) against lymphoma, colorectal and lung cancers, an anti-TRAIL-R1 (mapatumumab) or an anti-TRAIL-R2 (anti-DR5) (tigatuzumab) against several solid tumors (63).